Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: A phase 2, randomised, double-blind, placebo-controlled study

The Lancet Oncology

Volumn 13, Issue 2, 2012, Pages 154-162

  Gotlieb, Walter H ^a   Amant, Frederic ^b   Advani, Suresh ^c   Goswami, Chanchal ^d   Hirte, Hal ^e   Provencher, Diane ^f   Somani, Naresh ^g   Yamada, S Diane ^h   Tamby, Jean Francois ⁱ   Vergote, Ignace ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^d B P Poddar Hospital and Medical Research Ltd   (India)

^e JURAVINSKI CANCER CENTRE   (Canada)

^f NOTRE DAME HOSPITAL   (Canada)

^g Bhagwan Mahaveer Cancer Hospital and Research Centre   (India)

^h UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

ⁱ SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; PLACEBO; PLACENTAL GROWTH FACTOR; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; ASTHENIA; ASYMPTOMATIC DISEASE; CONTROLLED STUDY; DEHYDRATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE FISTULA; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OVARY CANCER; PARACENTESIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEPSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PATIENT SAFETY; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856509199     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70338-2     Document Type: Article

References (28)

1. Gotlieb WH, Feldman B, Feldman-Moran O, et al. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynecol Oncol 1998, 71:381-385.
2. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010, 127:2209-2221.
3. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005, 11:6966-6971.
4. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999, 85:178-187.
5. Roy H, Bhardwaj S, Yla-Herttuala S Biology of vascular endothelial growth factors. FEBS Lett 2006, 580:2879-2887.
6. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999, 6:373-378.
7. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000, 60:5334-5339.
8. Yukita A, Asano M, Okamoto T, Mizutani S, Suzuki H Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Res 2000, 20:155-160.
9. Numnum TM, Rocconi RP, Whitworth J, Barnes MN The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006, 102:425-428.
10. Bellati F, Napoletano C, Ruscito I, et al. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs 2010, 28:887-894.
11. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 2008, 111:530-532.
12. Kesterson JP, Mhawech-Fauceglia P, Lele S The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol 2008, 111:527-529.
13. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99:11393-11398.
14. Verheul HM, Hammers H, van Erp K, et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007, 13:4201-4208.
15. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
16. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9:5721-5728.
17. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003, 100:7785-7790.
18. Colombo N, Mangili G, Mammoliti S, et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol 2011, published online November 20. 10.1016/j.ygyno.2011.11.021.
19. Crawford B, Piault E, Corson H, Gotlieb W. The development of the Ascites Impact Measure questionnaire to assess patient symptoms that trigger a paracentesis. International Society for Quality Life Research; London, UK; Oct 27-30, 2010. Abstract 1596.
20. Piault E, Yeh Y, Crawford B, Joulain F, Gotlieb W. Psychometric validation of the Ascites Impact Measure questionnaire to assess patient symptoms that trigger a paracentesis. International Society for Quality Life Research; London, UK; Oct 27-30, 2010. Abstract 1616.
21. Ginsberg JM, Chang BS, Matarese RA, Garella S Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983, 309:1543-1546.
22. Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. Proc Am Soc Clin Oncol 2007, 25(suppl). abstr 5508.
23. Townsley C, Hirte H, Hoskins P, et al. A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: a study of the Princess Margaret Hospital Phase II Consortium. Proc Am Soc Clin Oncol 2009, 27(suppl). abstr 5591.
24. De Groot JF, Wen PY, Lamborn K, et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. Proc Am Soc Clin Oncol 2008, 26(suppl). abstr 2020.
25. Tang P, Cohen SJ, Bjarnason GA, et al. Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): a PMH phase II consortium trial. Proc Am Soc Clin Oncol 2008, 26(suppl). abstr 4027.
26. Tarhini AA, Christensen S, Frankel P, et al. Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin. Proc Am Soc Clin Oncol 2009, 27(suppl). abstr 9028.
27. Hapani S, Chu D, Wu S Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009, 10:559-568.
28. Diaz JP, Tew WP, Zivanovic O, et al. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol 2010, 116:335-339.